216 related articles for article (PubMed ID: 25292435)
1. Improving postapproval drug safety surveillance: getting better information sooner.
Hennessy S; Strom BL
Annu Rev Pharmacol Toxicol; 2015; 55():75-87. PubMed ID: 25292435
[TBL] [Abstract][Full Text] [Related]
2. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
4. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
5. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
Moore TJ; Furberg CD
Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
[TBL] [Abstract][Full Text] [Related]
6. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
[TBL] [Abstract][Full Text] [Related]
7. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection.
Xu R; Wang Q
BMC Bioinformatics; 2014 Jan; 15():17. PubMed ID: 24428898
[TBL] [Abstract][Full Text] [Related]
8. The utilization and challenges of Japan's MID-NET
Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
[TBL] [Abstract][Full Text] [Related]
9. A data-driven method to detect adverse drug events from prescription data.
Zhan C; Roughead E; Liu L; Pratt N; Li J
J Biomed Inform; 2018 Sep; 85():10-20. PubMed ID: 30016721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
11. Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?
Leite A; Thomas SL; Andrews NJ
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):25-29. PubMed ID: 29193554
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Communicating vaccine safety - the Vienna Vaccine Safety Initiative.
Rath B
Curr Drug Saf; 2015; 10(1):3-4. PubMed ID: 25859667
[No Abstract] [Full Text] [Related]
13. [Safety of medicinal products and reporting of adverse drug reactions].
Skibicka I; Maciejczyk A
Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
[TBL] [Abstract][Full Text] [Related]
14. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
Hauben M; Reich L; Chung S
Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
[TBL] [Abstract][Full Text] [Related]
17. Evolving paradigms in pharmacovigilance.
Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
[TBL] [Abstract][Full Text] [Related]
18. [Drug safety: from development to clinical use].
Ovchinnikova EA; Gerasimov VB
Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
[No Abstract] [Full Text] [Related]
19. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?
Coloma PM; Trifirò G; Patadia V; Sturkenboom M
Drug Saf; 2013 Mar; 36(3):183-97. PubMed ID: 23377696
[TBL] [Abstract][Full Text] [Related]
20. Encouraging spontaneous reporting of adverse effects.
Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
